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Abstract. Mass azithromycin distribution has been shown to reduce all-cause mortality in preschool children in sub-
Saharan Africa. However, substantial heterogeneity in the apparent effect has been noted across geographic settings,
suggesting a greater relative benefit in higher mortality settings. Here, we evaluated the relationship between the un-
derlyingmortality rate and the efficacy of azithromycin for the prevention of childmortality using data frommultiple sites in
Ethiopia, Malawi, Niger, and Tanzania. Between regions, we find no strong evidence of effect modification of the efficacy
of azithromycin distribution for the prevention of child mortality by the underlying mortality rate (P = 0.12), although a
modest effect is consistentwith our findings. Highermortality settings could beprioritized, however, because of the larger
number of deaths which could be averted with azithromycin distribution.
INTRODUCTION
Small trials of mass azithromycin distribution for trachoma
control suggested that mass azithromycin may reduce post-
neonatal childhood mortality.1–3 In the original primary anal-
yses, the Trachoma Amelioration in northern Amhara (TANA)
study demonstrated an odds ratio of 0.51 for mortality in the
azithromycin treatment group (95% CI: 0.29–0.90), for an
overall reduction in child mortality in communities receiving
azithromycin comparedwith delayed azithromycin. In theNiger
component of the Partnership for the Rapid Elimination of
Trachoma (PRET) study, biannual treatment of children led to a
mortality rate ratio of 0.81 (95% CI: 0.66–1.0), an overall re-
duction inchildmortalitycomparedwithannual treatmentof the
entire community. This findingwas confirmed in theMacrolides
Oraux pour Réduire les Décès avec un Oeil sur la Résistance
(MORDOR) study, a larger three-country study that demon-
strateda13.5%(95%CI: 6.7–19.8%) reduction inmortalitywith
biannual distributions4 in children aged 1–59 months.
Overtreatment with antibiotics has clear downsides. Dis-
tribution of azithromycin for trachoma control has been shown
to select for macrolide resistance in some organisms.5–8
However, identifying areas which maximize the efficacy of
azithromycin for prevention of child mortality could aid in
limiting distributions to regionswhere itmaybemost effective,
and thus limit antibiotic consumption. In both subgroup anal-
yses of MORDOR and the pooled analysis,9 effects appeared
to be larger in areas with higher mortality. However, as child-
hood mortality is a statistically rare event even in high-burden
settings, these analyses were not designed to provide evi-
dence of a statistically significant relationship between mor-
tality rate and efficacy of azithromycin distribution. Here, we
assess the dependence of the efficacy of mass azithromycin
distributions on the underlying childhood mortality rate in
three trials that have evaluated azithromycin for the prevention
of child mortality.1,2,4
METHODS
Data. Trachoma Amelioration in Northern Amhara.1 Com-
munities in the Goncha Siso Enese woreda of Amhara,
Ethiopia, were randomized to one of four arms: 1) annual
azithromycin distribution to all individuals aged 1 year and
older, 2) biannual azithromycin distribution to all individuals
aged 1 year and older, 3) quarterly treatment of children aged
1–9 years, or 4) delayed treatment.
Communities were followed for 12 months. A door-to-door
census was conducted in all communities, and all-cause
mortality as per the census was a prespecified primary out-
come. Children younger than 12 months were not treated in
TANA, and thus were excluded from analysis. For this analy-
sis, we included only children aged 1–5 years.
Partnership for the Rapid Elimination of Trachoma.2
Communities in Matameye, Niger, were randomized to one of
four arms: 1) annual azithromycin distribution with an 80%
coverage target, 2) annual azithromycin distributionwith a 90%
coverage target, 3) biannual azithromycin distribution to chil-
drenaged6months to12yearswithan80%coverage target,or
4) biannual azithromycin distribution to children with a 90%
coverage target.10–12 Mortality was determined via a door-to-
door census conducted before each treatment phase. Com-
munities were followed for 36 months.
Macrolides Oraux pour Réduire les Décès avec unOeil sur la
Résistance4 communities in the districts of 1) Mangochi,
Malawi; 2) Boboye and Loga, Niger; and 3) Kilosa and Gairo,
Tanzania, were randomized to biannual mass azithromycin
distribution to all children aged 1–59 months or biannual
matching placebo. A house-to-house enumerative census
was conducted in 6-month study periods. At each follow-up
census, vital status (alive, dead, or unknown) was docu-
mented for children from previous censuses. The pre-
specified primary outcome was community-level all-cause
mortality as determined by the census.
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Each study was reviewed and approved by the applicable
institutional review boards, including the Committee on Hu-
man Research at the University of California, San Francisco
(TANA, PRET, MORDOR), the Ethiopian Science and Tech-
nology Commission (TANA), and the Institutional Review
Boards at Emory University (TANA, MORDOR), the College of
Medicine, University ofMalawi, Blantyre (MORDOR), theNiger
Ministry of Health (PRET, MORDOR), the Tanzanian National
Institute forMedical Research (MORDOR), the LondonSchool
of Hygiene and Tropical Medicine (MORDOR), and the Johns
Hopkins University School of Medicine (MORDOR). Complete
methods for each study have been previously reported.1,2,4
Statistical analysis. For the three MORDOR study sites,
communities were aggregated into zones. We divided the
range of longitude and latitude for each country into equal
segments, resulting in an r × c grid which defines a zone. If
fewer than 10 communities were assigned to a given grid
square, that grid square was merged with the neighboring
square with the fewest number of communities (randomly
breaking ties). We chose a finer resolution for countries with a
larger number of deaths (4 × 4 for Tanzania, 4 × 5 for Malawi,
and 5 × 5 for Niger), which resulted in 10 zones for each
country (after merging as needed). In sensitivity analyses, we
examined all combinations of 4, 5, and6 latitude and longitude
grid divisions for each country (729 possible grids in total),
conducting four replications for each. The smaller TANA and
PRET studies were not subdivided.
We tested the association between mortality reduction
(comparing azithromycin and placebo communities) and
baselinemortality as follows. For each zone, we estimated the
log relativemortality rate and the averagemortality rate in both
azithromycin andplacebocommunities. Because somezones
could contain zero deaths, we used the shrinkage estimator
log ðn1 + 1=2Þ=T1ðn2 + 1=2Þ=T2, where Ti is the person-time at risk in treatment
group i and ni is the number of deaths in group i. Asymptotic
errors of the mortality rate ratio were computed.13 We mod-
eled the treatment effect by zone using linear mixed effects
regression, with the average mortality rate per zone as a fixed
effect regressor.Weusedcountry, andwhennecessary study,
as a random effect, and weighted each observation by the
inverse of the estimated variance of the mortality rate ratio.
Analyses were conducted in R (v. 3.5 for Macintosh, R Foun-
dation for Statistical Computing, Vienna, Austria).
RESULTS
Data were obtained from TANA, PRET, and the three
countries of the MORDOR study. From TANA, 48 communi-
ties were included, providing 9,754 person-years of monitor-
ing of children from the age of 1–5 years (in contrast to the
primary analysis, for ages 1–9 years). Between May 2006 and
May 2007, 62 deaths were observed in this age group. From
PRET, 48 communities were included, providing 11,872
person-years of monitoring for individuals aged 6 months
through 4 years. A total of 404 deathswere observed between
June 2010 and January 2013. From MORDOR, 1,512 com-
munities were included in the analysis, 323,302 person-years
were monitored, and 5,020 deaths were observed from De-
cember 2014 to July 2017 (Table 1). Azithromycin coverage
exceeded 80% (Table 1). For the MORDOR communities of
Niger, Malawi, and Tanzania, we analyzed 12, 11, and eight
zones, respectively. The median number of deaths by zone
was 327 (range 102–516) for Niger, 87 deaths (range 29–202)
for Malawi, and 34.5 deaths (range 7–116) for Tanzania. The
country-specific median total person-time per zone was
11,142 (range 3,271–24,440) person-years for Niger, 10,186
(range 4,765–18,141) person-years for Malawi, and 8,311
(range 999–17,711) person-years for Tanzania.
Figure 1 shows the effect sizes as a function of baseline
mortality. We found no convincing evidence that the baseline
mortality rate modified the effect of azithromycin on mortality
(P=0.12). This findingwasunchangedwhencontrolling for the
mean age of the enrolled children in each zone (P = 0.11). We
also foundmodest evidenceof adifferencewhenwe restricted
to the three MORDOR sites (P = 0.039) combined (although
not compelling, given multiple comparisons correction). We
found no evidence of a difference when we restricted to Niger
alone (P = 0.34). In an analysis restricted only to children
younger than 1 year in MORDOR, there was no evidence of
effect modification by the baseline mortality rate (P = 0.60).
When restricting to children aged 2–4 years, we findP= 0.018.
Similar findings were obtained for other choices of geo-
graphic zones. Using a 4 × 4 grid for all countries yielded an
overall nonsignificant P-value of 0.078, whereas a 5 × 5 grid
yielded P = 0.16. Examining all 729 possible combinations of
grid sizes of four, five, or six divisions per axis (longitude or
latitude) for the three countries, only 24.7% of these analyses
yielded significance at the 0.05 level.
DISCUSSION
In this analysis, we found no compelling evidence that the
underlying mortality ratemodified the effect of azithromycin on
childmortality, althoughamodest effect isnot inconsistentwith
our findings. We note, however, that although the MORDOR
trial was not powered for detection of effect modification, the
findings we reported previously showed stronger evidence
when restricted toMORDORsitesalone.Thefindingsof the trial
exhibited considerable apparent heterogeneity in efficacy by
country,4 but in the reported prespecified secondary analysis,
country did notmodify the effect of treatment withinMORDOR.
An alternative analysis of the MORDOR results which included
data from other sources found broadly similar findings.14 Our
procedure is similar to that of theBland–Altmananalysis, based
onmodeling thedifference inmortality asa functionof themean
(by zone), athough modest bias may remain.
In a broad sense, areas with higher overall mortality may
have a larger proportion because of infectious causes. We
might expect no discernable benefit to mass azithromycin
distribution in areas of the developed world where infectious
disease causes a smaller portion of childhood deaths. Our
TABLE 1









MORDOR Niger 594 76,490 9.3 92–98
PRET Niger 48 13,488 10.9 79–96
MORDOR Tanzania 614 35,226 6.2 80–91
MORDOR Malawi 304 78,920 6.7 88–95
TANA Ethiopia 48 9,754 0 81–89
MORDOR=MacrolidesOrauxpourRéduire lesDécèsavecunOeil sur laRésistance;PRET=
Rapid Elimination of Trachoma; TANA = Trachoma Amelioration in Northern Amhara. The
number of randomization units is given in the Communities column. In the TANA study,
individuals younger than 1 year were not treated. Full details are provided elsewhere.1,2,4
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findingscannotpreciselyestimate the thresholdatwhichmortality
benefits become negligible, and do not imply a lack of benefit for
communities at the lower end of the range observed here.
Higher mortality areas clearly have themost to gain in terms
of absolute number of deaths averted, even if the relative ef-
ficacy of azithromycin was similar across mortality rates. Our
findings support prioritization of high childhood mortality re-
gions, without precluding efforts in regions with relatively
lower childhood mortality.
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